The Stage 2 trial for Technoderma's drug, TDM-105795, reveals positive outcomes for hair regeneration in individuals with pattern baldness.

Sangamo Therapeutics Reveals New Findings from Phase 1/2 STAAR Research for Fabry Disease Indicating Continuous Efficacy and Unique Safety Data.

Findings on CSL and Arcturus' sa-mRNA technology suggest extended immunity compared to standard mRNA COVID booster shots.

Incyte has declared the establishment of an asset acquisition deal with MorphoSys AG, granting Incyte unique worldwide privileges for the drug tafasitamab.

MorphoSys AG has officially declared that it has formed a strategic alliance through a Business Merger Contract with Novartis data42 AG and the principal entity, Novartis AG.

Henlius Confirms Phase 1 Pharmacokinetic Equivalence Trial of Denosumab HLX14 Achieves Positive Outcome.

Pliant Therapeutics Reports Positive Phase 2a INTEGRIS-PSC Trial Results for Bexotegrast in Primary Sclerosing Cholangitis with Suspected Liver Fibrosis.

Acepodia Reveals US Regulatory Approval for Pioneering Anti-EGFR Allogeneic Cell Treatment Trial, Designated as ACE2016.

Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.

4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.

Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.

European Medicines Agency Approves Review of Tisotumab Vedotin Filing for Relapsed or Spreading Cervical Cancer Therapy.